 Liyen Loh
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucosal-Associated Invariant T Cells | 13 | 2025 | 37 | 3.530 |
Why?
| | CD8-Positive T-Lymphocytes | 20 | 2023 | 900 | 2.140 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 13 | 2014 | 86 | 1.770 |
Why?
| | Simian Immunodeficiency Virus | 12 | 2014 | 88 | 1.730 |
Why?
| | Influenza, Human | 15 | 2024 | 622 | 1.560 |
Why?
| | Influenza A virus | 10 | 2022 | 107 | 1.440 |
Why?
| | Killer Cells, Natural | 7 | 2024 | 449 | 1.370 |
Why?
| | Immunity, Innate | 5 | 2024 | 828 | 1.000 |
Why?
| | Influenza A Virus, H7N9 Subtype | 5 | 2018 | 5 | 0.920 |
Why?
| | Th17 Cells | 1 | 2025 | 108 | 0.870 |
Why?
| | Leukocytes, Mononuclear | 7 | 2022 | 558 | 0.830 |
Why?
| | Colon | 1 | 2025 | 282 | 0.790 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 4 | 2023 | 336 | 0.770 |
Why?
| | Colitis | 1 | 2025 | 266 | 0.760 |
Why?
| | Alleles | 2 | 2024 | 891 | 0.760 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 7 | 2025 | 1040 | 0.750 |
Why?
| | Coculture Techniques | 2 | 2020 | 239 | 0.730 |
Why?
| | Gene Products, gag | 6 | 2012 | 36 | 0.710 |
Why?
| | Epitopes, T-Lymphocyte | 7 | 2022 | 181 | 0.700 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 623 | 0.640 |
Why?
| | Alveolar Epithelial Cells | 1 | 2020 | 114 | 0.600 |
Why?
| | Thymus Gland | 5 | 2024 | 312 | 0.550 |
Why?
| | Phenotype | 3 | 2024 | 3196 | 0.530 |
Why?
| | Immunologic Memory | 7 | 2020 | 353 | 0.490 |
Why?
| | Immunity, Mucosal | 1 | 2016 | 97 | 0.480 |
Why?
| | Macaca nemestrina | 13 | 2014 | 29 | 0.470 |
Why?
| | Interleukin-18 | 1 | 2016 | 236 | 0.460 |
Why?
| | T-Lymphocyte Subsets | 5 | 2024 | 417 | 0.460 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 6 | 0.410 |
Why?
| | Cytokines | 6 | 2025 | 2085 | 0.390 |
Why?
| | Spirometry | 5 | 2025 | 281 | 0.390 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2024 | 203 | 0.380 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2010 | 173 | 0.370 |
Why?
| | Pneumonia, Viral | 1 | 2016 | 373 | 0.360 |
Why?
| | Natural Killer T-Cells | 2 | 2022 | 67 | 0.350 |
Why?
| | Australia | 5 | 2024 | 315 | 0.350 |
Why?
| | Immunophenotyping | 4 | 2020 | 318 | 0.330 |
Why?
| | Cell Differentiation | 4 | 2024 | 1991 | 0.330 |
Why?
| | Single-Cell Analysis | 2 | 2024 | 313 | 0.320 |
Why?
| | Mice, Inbred C57BL | 7 | 2025 | 5757 | 0.310 |
Why?
| | Immunity, Cellular | 3 | 2018 | 268 | 0.310 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2021 | 137 | 0.300 |
Why?
| | Forced Expiratory Volume | 5 | 2025 | 531 | 0.300 |
Why?
| | Genes, gag | 1 | 2008 | 4 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2021 | 1091 | 0.300 |
Why?
| | Viruses | 2 | 2020 | 113 | 0.290 |
Why?
| | Granzymes | 2 | 2020 | 50 | 0.290 |
Why?
| | Animals | 25 | 2025 | 36940 | 0.280 |
Why?
| | Humans | 47 | 2025 | 137585 | 0.280 |
Why?
| | Lymphocyte Activation | 5 | 2020 | 1142 | 0.280 |
Why?
| | Vital Capacity | 4 | 2025 | 311 | 0.270 |
Why?
| | Interferon-gamma | 4 | 2020 | 789 | 0.270 |
Why?
| | Fetus | 3 | 2024 | 806 | 0.270 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1996 | 0.260 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2024 | 718 | 0.260 |
Why?
| | Cell Communication | 2 | 2020 | 315 | 0.250 |
Why?
| | Mutation | 6 | 2014 | 3958 | 0.250 |
Why?
| | Immunotherapy | 5 | 2024 | 641 | 0.250 |
Why?
| | Monocytes | 2 | 2020 | 563 | 0.240 |
Why?
| | Oceania | 1 | 2024 | 4 | 0.230 |
Why?
| | Receptors, KIR3DL1 | 1 | 2024 | 18 | 0.230 |
Why?
| | Mice, Knockout | 4 | 2025 | 3015 | 0.220 |
Why?
| | Vaccination | 5 | 2021 | 1381 | 0.220 |
Why?
| | Blood | 2 | 2019 | 107 | 0.220 |
Why?
| | Aging | 3 | 2020 | 1864 | 0.220 |
Why?
| | B-Lymphocytes | 2 | 2021 | 847 | 0.220 |
Why?
| | Mice | 8 | 2025 | 17787 | 0.210 |
Why?
| | Anus Neoplasms | 1 | 2024 | 33 | 0.210 |
Why?
| | Viral Load | 4 | 2024 | 466 | 0.210 |
Why?
| | Bronchodilator Agents | 2 | 2023 | 252 | 0.210 |
Why?
| | Lung Diseases, Obstructive | 1 | 2023 | 50 | 0.200 |
Why?
| | Virus Replication | 4 | 2024 | 483 | 0.200 |
Why?
| | Viremia | 3 | 2008 | 138 | 0.200 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 149 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 2 | 2024 | 67 | 0.190 |
Why?
| | Lymphocytes | 1 | 2024 | 397 | 0.190 |
Why?
| | Selection, Genetic | 1 | 2024 | 273 | 0.190 |
Why?
| | Cough | 1 | 2023 | 122 | 0.190 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 156 | 0.180 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4295 | 0.180 |
Why?
| | Influenza Vaccines | 3 | 2022 | 539 | 0.180 |
Why?
| | Airway Obstruction | 1 | 2023 | 162 | 0.180 |
Why?
| | DNA, Viral | 2 | 2014 | 364 | 0.170 |
Why?
| | Forkhead Box Protein O1 | 1 | 2021 | 33 | 0.170 |
Why?
| | Immunodominant Epitopes | 1 | 2020 | 27 | 0.170 |
Why?
| | HLA-B27 Antigen | 1 | 2020 | 16 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2021 | 4193 | 0.170 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2020 | 6 | 0.170 |
Why?
| | Cellular Senescence | 2 | 2021 | 189 | 0.160 |
Why?
| | Antibody Formation | 1 | 2021 | 298 | 0.160 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.160 |
Why?
| | Adult | 16 | 2025 | 37929 | 0.160 |
Why?
| | Genetic Variation | 1 | 2024 | 991 | 0.160 |
Why?
| | Lung | 5 | 2024 | 4060 | 0.160 |
Why?
| | HTLV-I Infections | 1 | 2019 | 24 | 0.150 |
Why?
| | Proviruses | 1 | 2019 | 14 | 0.150 |
Why?
| | HLA-B37 Antigen | 1 | 2018 | 1 | 0.150 |
Why?
| | HLA-A1 Antigen | 1 | 2018 | 4 | 0.150 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2019 | 28 | 0.150 |
Why?
| | SAIDS Vaccines | 2 | 2009 | 4 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 54 | 0.150 |
Why?
| | Clonal Selection, Antigen-Mediated | 1 | 2018 | 4 | 0.150 |
Why?
| | Mucous Membrane | 2 | 2022 | 125 | 0.140 |
Why?
| | Antibodies, Viral | 4 | 2018 | 625 | 0.140 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 146 | 0.140 |
Why?
| | Respiratory System | 1 | 2019 | 157 | 0.140 |
Why?
| | HIV Infections | 4 | 2014 | 2836 | 0.140 |
Why?
| | Virus Diseases | 1 | 2020 | 212 | 0.140 |
Why?
| | Cross Reactions | 2 | 2014 | 133 | 0.140 |
Why?
| | Aged | 10 | 2025 | 23961 | 0.130 |
Why?
| | Melanoma | 1 | 2024 | 760 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 257 | 0.130 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 10 | 0.130 |
Why?
| | Survival Analysis | 2 | 2018 | 1325 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 364 | 0.130 |
Why?
| | A549 Cells | 1 | 2016 | 66 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 855 | 0.130 |
Why?
| | Inflammation | 2 | 2025 | 2837 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 976 | 0.130 |
Why?
| | RNA, Viral | 2 | 2012 | 656 | 0.130 |
Why?
| | Minor Histocompatibility Antigens | 3 | 2022 | 48 | 0.120 |
Why?
| | Female | 18 | 2025 | 73304 | 0.120 |
Why?
| | Male | 17 | 2025 | 67762 | 0.120 |
Why?
| | Escherichia coli | 1 | 2020 | 815 | 0.120 |
Why?
| | AIDS Vaccines | 3 | 2010 | 52 | 0.120 |
Why?
| | Middle Aged | 10 | 2025 | 33479 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2014 | 148 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2018 | 252 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1242 | 0.110 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 20 | 0.110 |
Why?
| | HIV Antibodies | 1 | 2014 | 62 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 132 | 0.100 |
Why?
| | Poverty | 1 | 2017 | 521 | 0.100 |
Why?
| | Cohort Studies | 5 | 2025 | 5742 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 3412 | 0.090 |
Why?
| | Gene Expression Regulation | 4 | 2018 | 2607 | 0.090 |
Why?
| | Influenza B virus | 2 | 2022 | 44 | 0.090 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.090 |
Why?
| | Genetic Engineering | 2 | 2009 | 93 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1502 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2111 | 0.090 |
Why?
| | HIV-1 | 2 | 2014 | 864 | 0.080 |
Why?
| | Albuterol | 2 | 2023 | 110 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 5472 | 0.080 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.080 |
Why?
| | HIV | 2 | 2009 | 234 | 0.080 |
Why?
| | Chronic Disease | 2 | 2023 | 1793 | 0.080 |
Why?
| | Neoplasms | 1 | 2024 | 2671 | 0.070 |
Why?
| | Adoptive Transfer | 2 | 2020 | 219 | 0.070 |
Why?
| | HLA-A Antigens | 2 | 2022 | 55 | 0.070 |
Why?
| | Replicon | 1 | 2008 | 14 | 0.070 |
Why?
| | Young Adult | 6 | 2021 | 13209 | 0.070 |
Why?
| | West Nile virus | 1 | 2008 | 43 | 0.070 |
Why?
| | Vaccines, Synthetic | 1 | 2008 | 126 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1783 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2900 | 0.060 |
Why?
| | Oligopeptides | 1 | 2008 | 271 | 0.060 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2018 | 25 | 0.060 |
Why?
| | Peptides | 3 | 2022 | 985 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1007 | 0.060 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2024 | 19 | 0.060 |
Why?
| | Oleic Acid | 1 | 2024 | 40 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2181 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 554 | 0.050 |
Why?
| | Occupations | 1 | 2023 | 49 | 0.050 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 128 | 0.050 |
Why?
| | Signal Transduction | 1 | 2016 | 5079 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 98 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 171 | 0.050 |
Why?
| | Quality of Life | 2 | 2025 | 2892 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2021 | 2139 | 0.050 |
Why?
| | Risk Factors | 3 | 2023 | 10388 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7635 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2020 | 2475 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1774 | 0.050 |
Why?
| | Fetal Development | 1 | 2024 | 296 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Dyspnea | 1 | 2023 | 254 | 0.040 |
Why?
| | Cost of Illness | 1 | 2023 | 308 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 36 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 6828 | 0.040 |
Why?
| | Hong Kong | 1 | 2020 | 7 | 0.040 |
Why?
| | Malaysia | 1 | 2020 | 5 | 0.040 |
Why?
| | Singapore | 1 | 2020 | 22 | 0.040 |
Why?
| | Haloperidol | 1 | 2020 | 34 | 0.040 |
Why?
| | Viral Plaque Assay | 1 | 2020 | 31 | 0.040 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 390 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2020 | 156 | 0.040 |
Why?
| | Dogs | 1 | 2021 | 413 | 0.040 |
Why?
| | Gene Frequency | 1 | 2021 | 521 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2199 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 674 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 2019 | 13 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 405 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2018 | 37 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 218 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 499 | 0.040 |
Why?
| | Antibody-Producing Cells | 1 | 2018 | 30 | 0.040 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 38 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2018 | 28 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 452 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 40 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 68 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2018 | 84 | 0.030 |
Why?
| | Uterus | 1 | 2018 | 215 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 904 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 228 | 0.030 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2016 | 11 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 409 | 0.030 |
Why?
| | Antigens, CD1d | 1 | 2016 | 68 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 198 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 249 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2167 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1178 | 0.030 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 19 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 500 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2017 | 600 | 0.030 |
Why?
| | Antigens, CD | 1 | 2018 | 521 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 434 | 0.030 |
Why?
| | Hemagglutination Tests | 1 | 2014 | 7 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 744 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2014 | 80 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 948 | 0.030 |
Why?
| | Child | 2 | 2024 | 21935 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 6763 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2014 | 144 | 0.030 |
Why?
| | Smoking | 1 | 2021 | 1627 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1502 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 767 | 0.030 |
Why?
| | HLA Antigens | 1 | 2014 | 240 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 476 | 0.020 |
Why?
| | RNA | 1 | 2018 | 921 | 0.020 |
Why?
| | Critical Illness | 1 | 2018 | 811 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4030 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3295 | 0.020 |
Why?
| | MicroRNAs | 1 | 2016 | 692 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2009 | 45 | 0.020 |
Why?
| | Receptors, OX40 | 1 | 2008 | 15 | 0.020 |
Why?
| | Fusion Proteins, gag-pol | 1 | 2008 | 2 | 0.020 |
Why?
| | Viral Vaccines | 1 | 2008 | 98 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2008 | 84 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 353 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 384 | 0.020 |
Why?
| | Longevity | 1 | 2008 | 165 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 564 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 812 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4149 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2847 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 21513 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 10811 | 0.010 |
Why?
|
|
Loh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|